The estimated Net Worth of Travis Frey is at least $445 millier dollars as of 1 December 2020. Dr Frey owns over 150 units of Calyxt Inc stock worth over $18,270 and over the last 6 years he sold CLXT stock worth over $0. In addition, he makes $426,757 as Chief Technology Officer at Calyxt Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr D CLXT stock SEC Form 4 insiders trading
Dr has made over 14 trades of the Calyxt Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 150 units of CLXT stock worth $569 on 1 December 2020.
The largest trade he's ever made was buying 550 units of Calyxt Inc stock on 13 January 2020 worth over $3,966. On average, Dr trades about 116 units every 13 days since 2019. As of 1 December 2020 he still owns at least 2,900 units of Calyxt Inc stock.
You can see the complete history of Dr Frey stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Travis J. Frey Ph.D. biography
Dr. Travis J. Frey Ph.D. is the Chief Technology Officer at Calyxt Inc.
What is the salary of Dr D?
As the Chief Technology Officer of Calyxt Inc, the total compensation of Dr D at Calyxt Inc is $426,757. There are 5 executives at Calyxt Inc getting paid more, with James Blome having the highest compensation of $4,488,350.
How old is Dr D?
Dr D is 43, he's been the Chief Technology Officer of Calyxt Inc since . There are 12 older and 3 younger executives at Calyxt Inc. The oldest executive at Calyxt Inc is Philippe Dumont, 68, who is the Independent Director.
What's Dr D's mailing address?
Travis's mailing address filed with the SEC is Mount Ridge Road, Roseville, Ramsey County, Minnesota, 55113-5499, United States.
Insiders trading at Calyxt Inc
Over the last 7 years, insiders at Calyxt Inc have traded over $2,578,214 worth of Calyxt Inc stock and bought 116,475 units worth $1,447,167 . The most active insiders traders include Kimberly K. Nelson, Daniel F Voytas et Yves J Ribeill. On average, Calyxt Inc executives and independent directors trade stock every 23 days with the average trade being worth of $35,853. The most recent stock trade was executed by Yves J Ribeill on 19 September 2022, trading 30,000 units of CLXT stock currently worth $7,200.
What does Calyxt Inc's logo look like?
Complete history of Dr Frey stock trades at Calyxt Inc
Calyxt Inc executives and stock owners
Calyxt Inc executives and other stock owners filed with the SEC include:
-
James Blome,
Chief Executive Officer, Director -
William Koschak,
Chief Financial Officer -
Debra Frimerman,
General Counsel -
Kimberly Nelson,
Independent Director -
William F. Koschak,
Chief Financial Officer -
Dr. Travis J. Frey Ph.D.,
Chief Technology Officer -
Daniel Voytas,
Chief Scientific Officer -
Philippe Dumont,
Independent Director -
Yves Ribeill,
Chairman of the Board -
Christopher Neugent,
Independent Director -
Anna Kozicz-Stankiewicz,
Independent Director -
Jonathan Fassberg,
Independent Director -
Chris Tyson,
IR Contact Officer -
Laurent Arthaud,
Director -
Bobby Williams,
Director - Gene Editing -
Vince Restucci,
Vice President of Agronomy Services -
Sarah Reiter,
Vice President - Business Development -
Travis Frey,
Chief Technology Officer -
Keith Blanks,
Senior Vice President of Sales and Marketing -
Gerry Nuovo,
Sr. VP of Bus. Devel. -
Dr. Stephen M. Bravo,
Chief Medical Officer -
Trina Lundblad,
Director of Communications -
Debra H. Frimerman,
Gen. Counsel & Corp. Sec. -
Dr. Daniel F. Voytas Ph.D.,
Founder, Chief Science Officer & Chair of Scientific Advisory Board -
Michael Allen Carr,
Pres, CEO & Director -
Michael A. Carr,
President and CEO -
Manoj Sahoo,
Chief Commercial Officer -
Alain Godard,
Director -
Bryan W.J. Corkal,
Chief Financial Officer -
Michel Arbadji,
Director of Business Developme -
Federico A. Tripodi,
Chief Executive Officer -
Glenn R Bowers,
Vice President of Breeding -
S.A. Cellectis,
10% owner